Prostaglandin E₂ Inhibits Prostate Cancer Progression by Countervailing Tumor Microenvironment-Induced Impairment of Dendritic Cell Migration through LXRα/CCR7 Pathway

Kuang Youlin®, He Weiyang, Liang Simin, and Gou Xin

Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Correspondence should be addressed to Kuang Youlin; kyl361@163.com

Received 1 December 2017; Revised 11 February 2018; Accepted 20 February 2018; Published 4 April 2018

Academic Editor: Maria Cristina Gagliardi

Copyright © 2018 Kuang Youlin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Migration and homing of dendritic cells (DCs) to lymphoid organs are quite crucial for T cell-induced immune response against tumor. However, tumor microenvironment can make some tumor cells escape immune response by impairing DC migration. Prostaglandin E₂ (PGE₂) plays important roles in initiating and terminating inflammatory responses. In this study, we investigated whether PGE₂ could inhibit murine prostate cancer progression by countervailing tumor microenvironment-induced impairment of dendritic cell migration. We found that murine prostate cancer cell line RM-1-conditioned medium impaired chemotactic movement of marrow-derived DCs and splenic cDCs toward CC chemokine receptor-7 (CCR7) ligand CCL19 in vitro and migration to draining lymph gland in vivo. Meanwhile, it also induced LXRα activation and CCR7 inhibition on maturing DCs. However, the treatment of PGE₂ rescued this impairment of DC migration with upregulation of CCR7 and inhibition of LXRα. Further, it was observed that PGE₂ also increased MMP9 expression and activated Notch1 signaling on DCs. In RM-1-bearing mouse model, PGE₂ treatment was identified to inhibit tumor growth and induce more tumor-infiltrating T cells and CD11c dendritic cells in tumor sites. Therefore, our findings may demonstrate a new perspective for therapeutic interventions on prostate cancer immunoescape.

1. Introduction

Dendritic cells (DCs) are known as the most potent antigen-presenting cells at present and play a central role in tumor-related immune response [1]. Following various antigens such as tumor-associated antigen (TAA) uptake in the peripheral tissue, immature DCs then mature and subsequently move to the secondary lymphoid tissue where they prime T cell response via presenting the antigenic peptides to T-lymphocytes in an MHC-restricted pattern. It was observed that the ability of DCs to initiate an immune response depends on their migration to draining lymph node [2] or immune escape could occur, which frequently is present in growing tumors such as prostate cancer (PCa) [3]. Evidences show that products of lipid and cholesterol metabolism have been demonstrated to cause immunosuppressive effects, including unable to stimulate allogeneic T cells effectively or present TAA as a result of a reduced antigen-processing ability of DCs [4].

Liver X receptors (LXRs) (LXRα and LXRβ), members of the nuclear receptor transcription factor superfamily, are important regulators of cholesterol, fatty acid, and glucose homeostasis that could be activated by oxidized cholesterol (oxysterols) [5]. LXRβ is expressed ubiquitously, whereas LXRα has been detected in the liver, adipose tissue, adrenal glands, the intestine, the lungs, and cells of myelomonocytic lineage [6]. It has been demonstrated that LXRs modulate innate and adaptive immune responses in inflammatory and autoimmune diseases [7]. In addition, studies have reported that LXRs can also promote the elimination of apoptotic cells by DCs and macrophages, thus maintaining immune tolerance [8], and block the proliferation of T and
2 B cells undergoing activation in physiologic conditions [9]. Meanwhile, LXRαs can inhibit cancer cell proliferation, which is demonstrated in vitro in plenty of human cancer cells, such as colon and breast cancer cells, T- and B-chronic lymphocytic leukemia (CLL), glioblastoma, and prostate cancer cells [10].

PGE$_2$, a metabolite of arachidonic acid, plays important roles in initiating and terminating inflammatory responses [11]. PGE$_2$ promotes the ability of DCs to preferentially attract the inhibitory regulatory T cell (Treg) subset of CD4$^+$ T cells and to directly improve the development of Tregs [12, 13]. PGE$_2$ can also synergize with tumor necrosis factor-α (TNFα) in the induction of DC maturation and in enhancing CCR7 expression [14]. Based on these observations, PGE$_2$ is frequently included in the cytokine cocktails used to produce mature DCs for clinical use as vaccines against cancer [15].

Prostate cancer (PCa) is the most frequently diagnosed cancer in old men and also the second leading cause of male cancer death in the Western countries [16]. Recently, evidence shows that some kinds of cancer, such as melanoma, colon, lung, and kidney tumors inhibit the function of DCs through LXR activation by releasing LXR ligands or oxysterols [17]. Data also indicate that human prostate cancer cells can cause apoptotic death of DCs and markedly inhibit the generation of DCs in cultures [18, 19]. As PGE$_2$ plays key roles in inflammation and tumor biology, we aimed to elucidate the role of PGE$_2$ on DC migration affected by murine prostate cancer cell line RM-1 and its antitumor effects.

2. Materials and Methods

2.1. Animals and Cell Lines. Female C57BL/6 (H-2 K$^b$) mice, 6–8 weeks old, were obtained from Shanghai SLAC Laboratory Animal Co. Ltd. (Shanghai, China). Animals were maintained at the Central Animal Facility of Chongqing Medical University according to standard guidelines, and experiments were conducted according to the guidelines of the China Council for Animal Care. RM-1, a murine prostate cancer cell line, was obtained from the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in RPMI-1640 medium with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO$_2$.

2.2. DC Generation. Mouse bone marrow-derived DCs were generated from bone marrow suspensions harvested from 6–8-week-old C57BL/6 mice according to the publication [20] with slight modifications. We followed the methods of Youlin et al. [21, 22]. Briefly, bone marrow cells were harvested from femurs and tibias, depleted of red blood cells, and washed twice in PBS. Cells were resuspended in a DC medium consisting of RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco, America), 10 ng/ml mGM-CSF (R&D Systems, USA), 10 ng/ml mIL-4 (R&D Systems, USA), and 50 mM 2-mercaptoethanol, 100 IU/ml penicillin, and 100 μg/ml streptomycin and cultured (37°C, 5% CO$_2$) in 6-well plates at 1×10$^5$ cells/3 ml/well. On days 3 and 5 of culture, floating cells were gently removed, and fresh mGM-CSF/mIL-4-containing medium was added. On day 6, nonadherent cells and loosely adherent proliferating DC aggregates were collected as immature DCs (iDCs). iDCs were then activated by the inclusion of 10 ng/ml LPS and 1 μg/ml PGE$_2$ (Sigma, USA) for another 48 h culture in the presence or absence of conditioned medium from the RM-1.

Spleen DCs were generated as described [23, 24]. Briefly, the spleen tissues were cut into small fragments and digested with collagenase D (Roche, Switzerland). Cells then were centrifuged and resuspended in 5 ml of a 1.077 histopaque (Sigma, USA). An additional 5 ml histopaque was layered below, and the culture medium was layered above the cell suspension, which was then centrifuged. The light density fraction was incubated with the following FITC-conjugated monoclonal antibodies (mAbs) (BD Pharmingen, USA): anti-CD3 (17A2), anti-Tly1.1 (OX-7), anti-B220 (RA3-6B2), anti-Gr-1 (RB68C5), anti-CD49b (DX5), and anti-TER-119 (TER-119). The lineage CD11c$^+$ cells were defined as cDCs. The analysis was carried out on a FACS Aria II (Becton Dickinson, San Diego, CA).

2.3. siRNA. 10 μM LXR-a siRNA (Santa Cruz, California) was added to 300 μl siRNA Transfection Medium (Santa Cruz, California), mixed gently, and incubated at room temperature for 20 min. The scramble siRNA was used as control. The mixture was then added dropwise to the plates with gentle shaking. The transfection media were removed after incubation for 24 h at 37°C, and the cells were transfected again following the same protocol. After another 48 h, the cells were collected for analysis.

2.4. Western Blot Analysis. Cell lysates were prepared. Total cellular proteins (50 μg) were subjected to SDS-PAGE and transferred to nitrocellulose membranes (Amersham, USA). Specific polyclonal antibody against LXRα, CCR7, ABCG1, ABCA1, MMP9, and Notch1 cleavage (Cell Signaling, Boston, USA) diluted in TBS-T containing 5% nonfat milk was used to detect indicated proteins. The appropriate horseradish peroxidase- (HRP-) conjugated IgG was used as the secondary antibody. An antibody on a membrane was visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA). Western blot for β-actin was used as an internal sample. The quantified densitometry ratio of a target protein to the internal sample was analyzed by Quantity One 4.62 software (Bio-Rad, USA).

2.5. Surface Marker Analysis of DCs. For phenotypic analyses by flow cytometry, DCs (5×10$^5$) were stained for 30 min on ice with FITC- or PE-labeled monoclonal antibodies specific for CD11c, CD80, CD86, and CCR7 (BD Pharmingen). After washing three times in PBS, the cells were analyzed by flow cytometry. Isotype-matched monoclonal antibodies were used as controls.

2.6. Transwell Migration Assay. 1×10$^5$ mature DCs were seeded into a transwell (Corning, USA) with a pore size of 5 μm. DCs were allowed to migrate towards chemokine-free RPMI or towards 200 ng/ml CCL19 in RPMI for 3 h at 37°C as described elsewhere [25]. Migrated DCs were harvested
from the lower chamber of the transwell and counted by flow cytometry. The percentage of migration was evaluated by the way that the number of migrated DCs was divided by the total number of cells added to the transwell [26].

2.7. DC Homing Assay. LPS-activated DCs with conditioned medium from the RM-1 treated or untreated were labeled with 5 μM of carboxyfluorescein diacetate succinimidyl ester (CFSE) (Sigma, USA) in suspension for 10 min at room temperature and then injected (1 × 10^6) subcutaneously in the hind leg footpad of C57BL/6 mice. 36 h postinjection mice were sacrificed to isolate popliteal lymph nodes and mechanically disaggregated as well as treated with collagenase A (1 mg/ml) and DNase (0.4 mg/ml) mixture in HBSS medium with 20% FBS for 60 min. Single cells were analyzed by flow cytometry as described above.

2.8. Tumor Growth in Mouse Xenograft Model. Mice (5 in each group) were shaved on the back and challenged subcutaneously with 2 × 10^5 RM-1 cells in PBS. PEG2 at 100 μl of 0.15 μg/ml or PBS was then intraperitoneally contralateral every 2 d in total 6 times starting 7d after tumor infusion. Tumor size was evaluated by measuring perpendicular diameters by a caliper. Mice were killed when the tumors displayed severe ulceration or reached a size of 1200 mm².

2.9. Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue cancer blocks were cut 4 μm thick sections and mounted on glass slides. After mounting, they were kept in an oven at 70°C for 2 h. Sections were deparaffinized in xylene and rehydrated. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 min. Antigen retrieval was treated by microwave. Specific polyclonal antibody against CD3 and CD11c diluted in 1% phosphate-buffered saline/bovine serum albumin (1% PBS-BSA) at 1:50 was used for incubation overnight. Sections were washed 3 times with PBS and incubated with biotin-labeled IgG for 1 h at room temperature. Then, the sections were stained by a streptavidin-peroxidase detection system (DakO, CA) after 3 washes with PBS. Negative control reactions replaced the primary specific antibody by PBS.

2.10. Statistical Analysis. SPSS13.0 was used for data variation analysis. Data are reported as the mean ± SD and were analyzed by the Student t-test; P values less than 0.05 were considered statistically significant.

3. Results

3.1. PGE2 Downregulates LXRα Expression and Activation in Maturing DCs Cultured in RM-1-Conditioned Medium. Firstly, to determine the effects of prostate cancer cell line RM-1 on LXRα expression in maturing DCs, we used the conditioned medium from RM-1 to culture the maturing DCs. The Western blot showed that RM-1-conditioned medium exhibited lower expression of LXRα, while cytophenotypic markers CD80 and CD86 were upregulated. However, the addition of PGE2 reversed this inhibition of LXRα expression but not that of CD80 and CD86 (Figure 2(a)). To further investigate whether CCR7 could be regulated by LXRα, we used LXRα siRNA to silence LXRα expression. Western blot showed that LXRα silencing reversed the inhibition of CCR7 expression induced by RM-1-conditioned medium in DCs (Figure 2(b)). Moreover, we found that PGE2 induced increasing expression of MMP9 and Notch1 cleavage (Figure 2(c)), which could be reversed by the addition of γ-secretase inhibitor RO4929097 (Figure 2(d)).

3.2. PGE2 Upregulates CCR7 Expression in Maturing DCs Cultured in RM-1-Conditioned Medium via Regulation of LXRα. Maturing DCs cultured in RM-1-conditioned medium exhibited lower expression of CCR7, while cytopherotypic markers CD80 and CD86 were upregulated. However, the addition of PGE2 reversed this inhibition of CCR7 expression but not that of CD80 and CD86 (Figure 2(a)). To further investigate whether CCR7 could be regulated by LXRα, we used LXRα siRNA to silence LXRα expression. Western blot showed that LXRα silencing reversed the inhibition of CCR7 expression induced by RM-1-conditioned medium in DCs (Figure 2(b)). Moreover, we found that PGE2 induced increasing expression of MMP9 and Notch1 cleavage (Figure 2(c)), which could be reversed by the addition of γ-secretase inhibitor RO4929097 (Figure 2(d)).

3.3. PGE2 Improves DC Migration In Vitro. Maturing DCs cultured in the presence or absence of conditioned medium from the RM-1 were seeded in the upper reservoirs of transwells, and the number of cells having migrated to the lower reservoir with chemokine CCL19 was assessed by flow cytometry. Data showed that DCs cultured in the RM-1-conditioned medium migrated significantly less efficiently towards the chemokine than that in the absence of RM-1-conditioned medium (Figure 3). However, the addition of PGE2 reversed this effect with increasing migrated DCs (Figure 3).

3.4. PGE2 Promotes DC Homing In Vivo. To evaluate whether RM-1-conditioned medium impaired DC migration to draining lymph nodes, FACS was used to analyze the draining lymph nodes collected from mice injected with CFSE-stained DCs activated with LPS in the presence or absence of RM-1-conditioned medium. DCs treated with RM-1-conditioned medium migrated poorly to the draining lymph node (Figure 4), but the addition of PGE2 reversed this effect with the promotion of DC homing (Figure 4).

3.5. PGE2 Inhibits RM-1 Cell Growth in Mice with Increased Tumor-Infiltrating T Lymphocytes in Tumor Sites. To confirm that the improvement of DC migration by PGE2 could further enhance T cell immune response against prostate cancer, RM-1 tumor-bearing mouse models were used for PGE2 treating. The result showed that PGE2 treatment significantly delayed tumor growth compared to controls (Figure 5(a)). Meanwhile, more tumor-infiltrated CD3⁺ lymphocytes and CD11c⁺ DCs were observed in tumor sites (Figure 5(b)).

4. Discussion

DCs are one of the most potent APCs for the induction of antitumor immune responses currently known and due to their strong antitumor effects; DCs emerged as promising candidates for the treatment of PCa patients. Consequently, several clinical trials enrolling PCa patients were conducted, which were based on the administration of DCs pulsed with
However, a number of treated PCa patients were resistant to DC-based immunotherapies, the exact reason of which remains unclear [29]. Here, we found that the conditioned medium from murine prostate cancer cell line RM-1 could inhibit DC migration to draining lymphoid (Figure 4). This impairment of the tumor-associated antigens [27, 28]. However, a number of treated PCa patients were resistant to DC-based immunotherapies, the exact reason of which remains unclear [29].

**Figure 1:** PGE$_2$ downregulates LXR$\alpha$ expression and activation. The maturing DCs were cultured in the conditioned medium from RM-1. The decrease in ABCG1 and ABCA1 as well as LXR$\alpha$ expression by PGE$_2$ was detected by Western blot.

|        | −  | +  | −  | +  |
|--------|----|----|----|----|
| PGE$_2$| 0.58 | 0.25 | 0.61 | 0.26 |
| RM-1   | 0.87 | 0.63 | 1.13 | 0.79 |

**Figure 2:** PGE$_2$ upregulates CCR7 expression via regulation of LXR$\alpha$ and Notch1. (a) Surface markers of CD80, CD86, and CCR7 in maturing DCs cultured in RM-1-conditioned medium were analyzed by flow cytometry. Data were presented as the mean ± SD of 3 independent experiments, each performed in triplicate (*$P$ < 0.05). (b) LXR$\alpha$ silencing partially reversed the inhibition of CCR7 expression induced by RM-1-conditioned medium in DCs. (c) Increase in expression of MMP9 and Notch1 cleavage by PGE$_2$ was analyzed by Western blot. (d) Notch1 cleavage inhibitor RO4929097 partially reversed the inhibition of CCR7 expression induced by RM-1-conditioned medium in DCs using Western blot.
assessed by inguinal lymph nodes collected from mice injected with DCs was the percentage of CFSE-positive DCs migrating to the draining (Figure 3). PGE2 promotes DCs homing in vivo. DCs were activated by the inclusion of 10 ng/ml LPS culture in the presence or absence of conditioned medium from the RM-1 as well as PGE2. Quantiﬁcation of the migration of DCs to 200 ng CCL19. Data were presented as the mean ± SD of 3 independent experiments, each performed in triplicate (*P < 0.05). BMDCs: bone marrow-derived DCs; cDCs: spleen conventional DCs.

Figure 4: PGE2 promotes DCs homing in vivo. DCs were activated by LPS in the presence or absence of conditioned medium from the RM-1 as well as PGE2 and stained with CFSE. The percentage of CFSE-positive DCs migrating to the draining lymph nodes was assessed by ﬂow cytometry. Data were presented as the mean ± SD (*P < 0.05). BMDCs: bone marrow-derived DCs; cDCs: spleen conventional DCs.

migratory ability of DCs toward draining lymphoid may result in a reduced antitumor immune response, because DC-induced potent immune response depends on their intact migration from peripheral tissues where they arrest foreign antigens to secondary lymphoid organs where T cell lives [2]. To rescue the migratory ability of DCs, PGE2 was added into the RM-1-conditioned medium. We found that PGE2 could improve the DC migration, increase tumor-inﬁltrated T lymphocytes in tumor sites, causing RM-1 tumor-bearing mouse model delayed tumor growth.

PGE2 is known to be crucial for immune responses, such as by increasing CCR7-driven DC migration and homing to draining lymph nodes [25, 30], efficient T cell activation [11, 13], keeping the gut mucosal barrier intact against colitis [30], and homeostasis [31]. Here, our study also showed that PGE2 reversed the inhibition of CCR7 in DCs from RM-1-conditioned medium (Figure 2(a)) and improved DC migration efﬁciently to the CCR7 ligand CCL19 (Figure 3). CCR7 is induced together with the maturation of DCs, which was characterized by the upregulated expression of MHC molecules and costimulatory molecules such as CD80, CD83, and CD86, as well as CCR7 [32, 33], and is essential for DC mobilization. The transfer of CCR7-deﬁcient DCs leads to the recovery of less than one-tenth the number of DCs from the lymph node compared with the transfer of CCR7+ DCs [34], and DCs differentiated from the bone marrow of CCR7-deﬁcient mice do not move to the draining lymph nodes following their subcutaneous injection or intratracheal instillation [35, 36]. The expression of CCR7 alone, however, is not sufﬁcient for DC migration, sole ligands of which, such as CC-chemokine ligand 19 (CCL19) and CCL21, are essentially involved. Here, we also showed that PGE2 upregulated MMP9, known to be important for DC migration [37]. However, the costimulatory molecules such as CD80 and CD86 were not restrained by RM-1-conditioned medium (Figure 2(a)).

Presently, though it is not totally clear how PGE2 regulates DC migration on a molecular level, PGE2 was shown to improve CCR7 signaling resulting in migration [38]. To further explore how PGE2 promotes CCR7 expression, we investigated LXRα. We found that RM-1-conditioned medium induced LXRα activation with increasing the expression of the LXR target genes ABCG1 and ABCA1. However, PGE2 reversed this activation with decreasing ABCG1 and ABCA1 expression and further expression of LXRα (Figure 1). Furthermore, after LXRα was speciﬁcally silenced by LXRα siRNA, the inhibition of CCR7 expression was rescued (Figure 2(b)). It demonstrated that PGE2 upregulated CCR7 expression in maturing DCs cultured in RM-1-conditioned medium via inhibiting LXRα. LXRα modulates innate and adaptive immune responses in inﬂammatory and autoimmune diseases [7]. In addition, data indicate that LXRα can also promote the elimination of apoptotic cells by DCs and macrophages, thus maintaining immune tolerance [8], and in vitro differentiation of human DCs in the presence of LXR agonists and LPS has been indicated to inﬂuence their T cell stimulatory ability [39]. Moreover, we discovered that the addition of PGE2 to RM-1-conditioned medium enhanced the expression of Notch1 cleavage (Figure 2(c)). Additionally, the expression of CCR7 was downregulated when the Notch1 cleavage was inhibited by γ-secretase inhibitor RO4929097 (Figure 2(d)). It has been studied that Notch activation upregulates CCR7 expression in leukemic cells [40]. Our data indicated that PGE2 preserved the activation
Figure 5: PGE$_2$ inhibits RM-1 cell growth in mice with increased tumor-infiltrating T lymphocytes in tumor sites. Mice were challenged subcutaneously with $2 \times 10^5$ RM-1 cells. PGE$_2$ at 100 $\mu$l of 0.15 $\mu$g $\mu$l$^{-1}$ or PBS was then intraperitoneally contralateral every 2 d in total 6 times starting. (a) The tumor volume was monitored. $*P < 0.05$. (b) Immunohistochemical analysis of CD3 and CD11c in tumor sections using anti-mouse CD3 and CD11c antibody staining (brown). Original magnification, 400x.
of Notch1 signaling in DCs in the presence of RM-1-conditioned medium that were presumably involved in the regulation of CCR7 expression.

5. Conclusions
Our findings may demonstrate a possible potential way of prostate cancer immunoecape or immune-tolerance in which prostate cancer impairs DC migration towards draining lymph nodes. At the same way, PGE₂ may be used as a new perspective for therapeutic interventions on prostate cancer immunoecape.

Conflicts of Interest
There is no potential conflict of interest in this paper.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (Grant no. 81302237) and the project of Chongqing Science and Technology Commission (no. cstc2016cjyA0864).

References
[1] E. Segura and S. Amigorena, "Cross-presentation in mouse and human dendritic cells," Advances in Immunology, vol. 127, pp. 1–31, 2015.
[2] G. J. Randolph, J. Ochando, and S. Partida-Sanchez, "Migration of dendritic cell subsets and their precursors," Annual Review of Immunology, vol. 26, no. 1, pp. 293–316, 2008.
[3] D. S. Vinay, E. P. Ryan, G. Pawelec et al., "Immune evasion in cancer: mechanistic basis and therapeutic strategies," Seminars in Cancer Biology, vol. 35, pp. S185–s198, 2015.
[4] D. L. Herber, W. Cao, Y. Nefedova et al., "Lipid accumulation and dendritic cell dysfunction in cancer," Nature Medicine, vol. 16, no. 8, pp. 880–886, 2010.
[5] C. Hong and P. Tontonoz, "Liver X receptors in lipid metabolism: opportunities for drug discovery," Nature Reviews Drug Discovery, vol. 13, no. 6, pp. 433–444, 2014.
[6] J. J. Repa and D. J. Mangelsdorf, "The role of orphan nuclear receptors in the regulation of cholesterol homeostasis," Annual Review of Cell and Developmental Biology, vol. 16, no. 1, pp. 459–481, 2000.
[7] K. E. Waddington, E. C. Jurry, and I. Pineda-Torra, "Liver X receptors in immune cell function in humans," Biochemical Society Transactions, vol. 43, no. 4, pp. 752–757, 2015.
[8] N. A-Gonzalez, S. J. Bensinger, C. Hong et al., "Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR," Immunity, vol. 31, no. 2, pp. 245–258, 2009.
[9] S. J. Bensinger, M. N. Bradley, S. B. Joseph et al., "LXR signaling couples sterol metabolism to proliferation in the acquired immune response," Cell, vol. 134, no. 1, pp. 97–111, 2008.
[10] T. Jakobsson, E. Treuter, J. A. Gustafsson, and K. R. Steffensen, "Liver X receptor biology and pharmacology: new pathways, challenges and opportunities," Trends in Pharmacological Sciences, vol. 33, no. 7, pp. 394–404, 2012.
[11] D. F. Legler, M. Bruckner, E. Uetz-von Allmen, and P. Krause, "Prostaglandin E₂ at new glance: novel insights in functional diversity offer therapeutic chances," The International Journal of Biochemistry & Cell Biology, vol. 42, no. 2, pp. 198–201, 2010.
[12] R. Muthuswamy, J. Urban, J. J. Lee, T. A. Reinhart, D. Bartlett, and P. Kalinski, "Ability of mature dendritic cells to interact with regulatory T cells is impaired during maturation," Cancer Research, vol. 68, no. 14, pp. 5972–5978, 2008.
[13] S. Sharma, S. C. Yang, L. Zhu et al., "Tumor cyclooxygenase-2/prostaglandin E₂-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer," Cancer Research, vol. 65, no. 12, pp. 5211–5220, 2005.
[14] R. Muthuswamy, J. Mueller-Berghaus, U. Haberkorn, T. A. Reinhart, D. Schadendorf, and P. Kalinski, "PGE₂ transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells," Blood, vol. 116, no. 9, pp. 1454–1459, 2010.
[15] T. Osaka, K. Nagaoka, M. Takahara et al., "Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors," Journal of Immunotherapy, vol. 38, no. 4, pp. 155–164, 2015.
[16] K. D. Miller, R. L. Siegel, C. C. Lin et al., "Cancer treatment and survivorship statistics, 2016," CA: A Cancer Journal for Clinicians, vol. 66, no. 4, pp. 271–289, 2016.
[17] E. J. Villablanca, L. Raccotta, D. Zhou et al., "Tumor-mediated liver X receptor-a activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses," Nature Medicine, vol. 16, no. 1, pp. 98–105, 2010.
[18] M. Aalamian, G. Pirtskhalashvili, A. Nunez et al., "Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells," The Prostate, vol. 46, no. 1, pp. 68–75, 2001.
[19] G. Pirtskhalashvili, G. V. Shurin, C. Esche et al., "Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins," British Journal of Cancer, vol. 83, no. 4, pp. 506–513, 2000.
[20] S. Nagaraj, V. Pisarev, L. Kinarsky et al., "Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors," Journal of Immunotherapy, vol. 30, no. 2, pp. 169–179, 2007.
[21] K. Youlin, Z. Jianwei, G. Xin et al., "4-1BB protects dendritic cells from prostate cancer-induced apoptosis," Pathology & Oncology Research, vol. 19, no. 2, pp. 177–181, 2013.
[22] K. Youlin, K. Jian, L. Siming et al., "Potent anti-prostate cancer immune response induced by dendritic cells transduced with recombinant adenoviruses encoding 4-1BBL combined with cytokine-induced killer cells," Immunotherapy, vol. 7, no. 1, pp. 13–20, 2015.
[23] L. Xu, M. Kwak, W. Zhang, P. C.-W. Lee, and J.-O. Jin, "Time-dependent effect of E. coli LPS in spleen DC activation in vivo: alteration of numbers, expression of co-stimulatory molecules, production of pro-inflammatory cytokines, and presentation of antigens," Molecular Immunology, vol. 85, pp. 205–213, 2017.
[24] K. Inaba, W. J. Swiggard, R. M. Steinman, N. Romani, and G. Schuler, "Isolation of dendritic cells," Current Protocols in Immunology, vol. 25, pp. I.3.7.3.7:1–I.3.7.3.7:15, 2001.
[25] D. F. Legler, P. Krause, E. Scandella, E. Singer, and M. Groettrup, "Prostaglandin E₂ is generally required for human dendritic cell migration and exerts its effect via EP2
and EP4 receptors,” The Journal of Immunology, vol. 176, no. 2, pp. 966–973, 2006.

[26] H. Schachtner, M. Weimershaus, V. Stache et al., “Loss of Gadkin affects dendritic cell migration in vitro,” PLoS One, vol. 10, no. 12, article e0143883, 2015.

[27] P. A. Lodge, L. A. Jones, R. A. Bader, G. P. Murphy, and M. L. Salgaller, "Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial," Cancer Research, vol. 60, no. 4, pp. 829–833, 2000.

[28] B. A. Tjoa, S. J. Simmons, V. A. Bowes et al., “Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides,” The Prostate, vol. 36, no. 1, pp. 39–44, 1998.

[29] H. Jähnisch, S. Füssel, A. Kiessling et al., “Dendritic cell-based immunotherapy for prostate cancer,” Clinical and Developmental Immunology, vol. 2010, article 517493, 8 pages, 2010.

[30] K. Kabashima, T. Saji, T. Murata et al., “The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut,” The Journal of Clinical Investigation, vol. 109, no. 7, pp. 883–893, 2002.

[31] C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001.

[32] S. Sozzani, P. Allavena, W. Luini et al., “Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties,” The Journal of Immunology, vol. 161, no. 3, pp. 1083–1086, 1998.

[33] S. Yanagihara, E. Komura, J. Nagafune, H. Watarai, and Y. Yamaguchi, "EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation," The Journal of Immunology, vol. 161, no. 6, article 9743376, pp. 3096–3102, 1998.

[34] A. Martín-Fontecha, S. Sebastiani, U. E. Höpken et al., "Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming," The Journal of Experimental Medicine, vol. 198, no. 4, pp. 615–621, 2003.

[35] L. Ohl, M. Mohaupt, N. Czeloth et al., "CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions," Immunity, vol. 21, no. 2, pp. 279–288, 2004.

[36] G. Hintzen, L. Ohl, M. L. del Rio et al., "Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node," The Journal of Immunology, vol. 177, no. 10, pp. 7346–7354, 2006.

[37] J. H. Yen, T. Khayrullina, and D. Ganea, "PGE2-induced metalloproteinase-9 is essential for dendritic cell migration," Blood, vol. 111, no. 1, pp. 260–270, 2008.

[38] E. Scandella, Y. Men, D. F. Legler et al., “CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2,” Blood, vol. 103, no. 5, pp. 1595–1601, 2004.

[39] R. Geyeregger, M. Zeyda, W. Bauer et al., "Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin," Blood, vol. 109, no. 10, pp. 4288–4295, 2007.

[40] S. Buonamici, T. Trimarchi, M. G. Ruocco et al., "CCR7 signaling as an essential regulator of CNS infiltration in T-cell leukaemia," Nature, vol. 459, no. 7249, pp. 1000–1004, 2009.